- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Leo to market AstraZeneca's psoriasis treatment outside the EU | ||
| Do | Merck collaborates to examine Keytruda in combination with investigational drug | ||
| Do | Traceability is key in the growing global cold chain market | ||
| Mi | EMA tells companies to declare peptone use in biologics fermentation | ||
| Mi | In riposte to AbbVie, Revance talks up prospects of biosimilar Botox | ||
| Mi | Court sides with Amgen in Enbrel biosimilar patent case | ||
| Di | Bayer acquires cell therapies developer BlueRock | ||
| Di | Expanded approval of Dupixent scratches an unmet itch | ||
| Di | Regenerative medicines global revenues down by 40%, but 'poised for growth' | ||
| 08.08. | BMS leases biologic development space in New Jersey to PTC | ||
| 08.08. | Pfizer ramps up bioprocessing capacity for DMD gene therapy trial | ||
| 08.08. | Vida generates $600m, triples assets to expand life sciences platform | ||
| 07.08. | BLA for Novartis' $2.1m gene therapy potentially contains accurate data | ||
| 07.08. | BLA for Novartis' $2.1m gene therapy potentially contains inaccurate data | ||
| 07.08. | Fujifilm aims to become a 'total healthcare company', acquires Biogen facility | ||
| 07.08. | EQT VIII Fund invests in Aldevron, supports capacity expansion | ||
| 07.08. | Singapore biomedical manufacturing up by 9.6% in 2019 | ||
| 05.08. | What it takes to lead a cell and gene therapy company | ||
| 02.08. | Genomic data on cancer treatment released to public | ||
| 01.08. | Lonza, Vineti team up to address risks in the 'vein-to-vein' supply chain | ||
| 01.08. | Lonza to continue narsoplimab manufacture for Omeros | ||
| 01.08. | WHO indicates preferred HIV treatment | ||
| 31.07. | Gilead's Yescarta edges ahead of Kymriah in CAR-T race | ||
| 30.07. | Sales of Keytruda leads Merck to strong Q2 | ||
| 29.07. | July roundup sees flurry of partnership deals |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
